Tag

HIV Research

Fenway’s Dr. Kenneth Mayer Receives HPTN’s Ward Cates Spirit Award

By | Fenway Health Newsroom, HIV/AIDS, HIV/AIDS, The Fenway Institute | No Comments
We are thrilled to announce that Kenneth Mayer, MD, Co-Chair and Medical Research Director at The Fenway Institute, has been honored by the HIV Prevention Trials Network (HPTN) with its first ever Ward Cates Spirit Award. This award recognizes a Network member who has made outstanding contributions to HPTN’s mission through public health advocacy, leadership, and mentoring. The Spirit Award is named for Willard (Ward) Cates Jr., MD, MPH, Distinguished Scientist and President Emeritus of FHI 360 and Principal Investigator of HIVNET’s International Master Contractor and HPTN from 1994 to 2006. Cates passed away in March of 2016. Winners of 
Read More

Spotlighting HIV/STI Prevention For Transgender Men

By | Fenway Health Newsroom, HIV/AIDS, HIV/AIDS, The Fenway Institute, Trans | No Comments
Transgender men and transmasculine individuals are all too often left out of the conversation around HIV and STI prevention. A new report led by researchers from The Fenway Institute hopes to address this knowledge gap by outlining the specific sexual health needs of this overlooked demographic. The report, titled LifeSkills for Men (LS4M): Pilot Evaluation of a Gender-Affirmative HIV and STI Prevention Intervention for Young Adult Transgender Men Who Have Sex with Men, is published in the Journal of Urban Health and is the first of its kind to explore HIV and STI prevention interventions focused on young adult transgender 
Read More

Fenway Health Observes World AIDS Day 2015

By | Fenway Health Newsroom, HIV/AIDS | No Comments
December 1st marks World AIDS Day – a time each year when we pause to reflect on the incredible progress made in the global battle against HIV/AIDS, and recommit to continue the fight until the epidemic is over. Though this disease is no longer the almost certain death sentence it once was, every new infection is one infection too many. For those with the means to access lifesaving medication, HIV/AIDS is a manageable chronic condition, but still one that can affect everyday life. For those who face financial, social, and geographical barriers to treatment, AIDS still claims lives around the 
Read More

AMP Study Explores Potency Of Antibodies In HIV Prevention

By | Fenway Health Newsroom, HIV/AIDS, HIV/AIDS, The Fenway Institute | No Comments
In a continuation of our decades-long commitment to treating and preventing HIV/AIDS, Fenway Health will soon serve as a testing site for a revolutionary new study that explores whether antibodies can be used to combat individual HIV infections. Also known as HVTN 703/HPTN 081, the AMP (Antibody Mediated Prevention) study tests the efficacy of an experimental antibody in protecting against HIV infection. “This study is particularly significant, since if it is successful, it will create a brand new way to protect people against HIV,” said Dr. Kenneth Mayer, Co-Chair and Medical Research Director at The Fenway Institute. “The work will 
Read More

PROUD Study Proves PrEP’s Efficacy In Real World Setting

By | Fenway Health Newsroom, HIV/AIDS, HIV/AIDS, The Fenway Institute | No Comments
Findings from a new open-label trial of pre-exposure prophylaxis (PrEP) could help erase any lingering doubts around the drug’s efficacy in preventing HIV infection outside of a controlled study environment. The PROUD study, which took place at 13 English sexual health clinics, was an open-label trial of PrEP, as opposed to the randomized placebo-controlled studies that have previously shown PrEP’s power in HIV prevention. In an open-label trial, all participants know that they are receiving the actual drug in question and not a placebo. The study was published in The Lancet, one of the world’s leading medical journals. A total 
Read More